Pharmas Get Additional Month To Comply With Indian Pricing Requirements
This article was originally published in PharmAsia News
Pharmaceutical companies have been granted an additional month to conform with National Pharmaceutical Pricing Authority requirements that they report manufacturing costs. Drug makers strongly objected to being required to meet the Jan. 31 deadline for supplying conversion, packing, processing and packing material costs to the agency. The NPPA has now extended the deadline to Feb. 28. The agency is required by law to revise its norms for the costs in determining the price caps to be imposed on drugs. (Click here for more
You may also be interested in...
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.
The European Medicines Agency will continue working over the Christmas period so that it can complete its assessment of the newly filed marketing applications for BioNTech/Pfizer’s and Moderna’s COVID-19 vaccines as soon possible.